Saturday, March 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

SLU Enrolling Volunteers for Plague Vaccine Study

by Global Biodefense Staff
July 23, 2013

Yersinia pestis - the cause of plagueThe Saint Louis University School of Medicine is enrolling volunteers for an initial safety and tolerability study of a vaccine for Plague; an infectious disease of animals and humans caused the bacteria Yersinia pestis.  

Like smallpox, plague bacteria have long been considered a potential bioterrorism threat. Pneumonic or inhaled plague is highly lethal if not treated within 18 hours of the onset of symptoms. Currently, there is no effective licensed vaccine that protects against pneumonic plague. 

In view of the seriousness of infection with Y. pestis, a substantial effort has been focused on the development of protective vaccines. The purpose of this study is to look at the safety and tolerability of an experimental vaccine that has not previously been given to humans.

SLU’s Center for Vaccine Development is enrolling healthy participants from 18 to 45 years of age. The Center notes that you cannot get infection of plague from the vaccine. Study participants will be monitored to assess tolerability and human immune response.

Read more: Saint Louis University Center for Vaccine Development

Tags: BioterrorismVaccinesY. pestis

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC